Targeting EGFR in Colorectal Cancer

In the United States, cancer is the most common cause of death among people under the age of 85 years, and colorectal cancer is the second most common cause of death from cancer.1 Chemotherapy for colorectal cancer has until recently typically consisted of the empirical use of cytotoxic agents guided by the results of controlled clinical trials. Cancer therapy has now entered a new era, however, owing to remarkable advances in our understanding of the nature of molecular and biochemical events involved in the process of carcinogenesis and tumor growth. Biologically targeted therapies are now commonly used as part of . . .